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A4-05 Surgery, Mon, 13:45 - 15:30
Preparation for a new TNM stage: The prognostic significance of 
multiple station N2 in stage IIIA non small cell lung cancer 
Lee, Jin Gu; Lee, Chang Young; Park, In Kyu; Kim, Dae Joon; Chung, 
Kyung Young
Department of Thoracic and Cardiovascular Surgery, Yonsei University 
College of Medicine, Seoul, Korea
Background: Stage IIIA non small cell lung cancer(NSCLC) is 
heterogenous diseases in one category. This study was conducted to 
determine the prognostic implication of the multiple station N2 lymph 
node metastasis in pathologic stage IIIA N2 NSCLC and to propose a 
new nodal stage in a new TNM stage.
Method: Three hundred and ﬁfty-eight patients with resected NSCLC 
who eventually proved to have pathologic stage IIIA N2 and stage IIIB 
disease were reviewed. The patients were divided into three groups: 
Single IIIA group are those who have single station N2 disease in stage 
IIIA NSCLC; Multiple IIIA group are those who have multiple station 
N2 disease in stage IIIA NSCLC; IIIB group are those who have stage 
IIIB NSCLC. Patients who received preoperative induction therapy 
were excluded from this study.
Result: Number of the patients in Single IIIA group was 175, in Mul-
tiple IIIA group 87, and in IIIB group 96. Between the three groups, 
there were no differences in sex, histopathology, tumor size, primary 
site, number of lymph nodes dissected and performed procedures 
(except 17 open and closure cases in IIIB group). In stage IIIA N2 
NSCLC(Single IIIA group and Multiple IIIA group), a log-rank test 
revealed that factors such as age>60, male, T stage, pneumonectomy, 
multiple station N2 were associated with poor survival rate. In multi-
variate analysis, age>60 (risk ratio=2.452, p=0.000), pneumonectomy 
(risk ratio=1.478, p=0.007), and multiple station N2 (risk ratio=2.089, 
p=0.004) were independent prognostic factors for poor survival rate. 
Multiple IIIA group (20.4%) had lower 5-year survival rate than 
Single IIIA group (33.8%) (p=0.016), but had no difference with IIIB 
group(15.5%) (p=0.577).
Conclusion: Multiple station N2 disease was important prognostic 
factor for poor survival rate in pathologic stage IIIA N2 non-small cell 
lung cancer. There was no difference in survival between multiple sta-
tion N2 stage IIIA and stage IIIB. 
We suggest that N2 lymph node should be divided into two categories: 
N2a and N2b; the former be deﬁned in a single station N2; the latter in 
multiple station N2, and that N2b be considered as N3 lymph node in a 
new TNM stage.
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Patients-oriented prospective study in comparison between two 
types of VATS lobectomy for clinical T1N0 lung cancer
Yamashita, Yoshinori1 Mukaida, Hidenori2 Egawa, Hiromi3 
Hirabayashi, Naoki2 Takiyama, Wataru2 
1 Hiroshima City Asa Hospital, Hiroshima, Japan 2 Surgery, Hiroshima 
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Background: Video assisted thoracic surgery (VATS) is not currently a 
standard operative procedure for lung cancer because of a few prospec-
tive comparison study. Moreover, it is still unresolved issue whether the 
degree of chest wall destruction by various VATS thoracotomy affects 
clinical outcomes. The variety of its technical approaches of video-as-
sisted thoracic surgery (VATS) lobectomy is also indicated depending 
on the facilities. Therefore, the clinical outcomes of VATS lobectomy 
were compared between two different methods of VATS lobectomy, 
which was determined by informed consent before the surgery. 
Methods: We experienced reviewed 74 consecutive patients with 
clinical T1N0M0 non-small cell lung cancer (NSCLC) that underwent 
either two levels of VATS lobectomy with mediastinal lymph adenecto-
my. By showing the patients an easy schema which says characteristics 
of each procedure to help their understanding, the selection was com-
pletely based on their decision before the surgery. Eighteen cases (AS-
SIST group) underwent lobectomy performed mainly using the light 
guide of thoracoscope in an anterolateral small thoracotomy (around 
10cm) with the use of a rib spreader. In 56 cases (PURE group), only a 
monitor was used during minithoracotomy (3-4cm), which is minimum 
access to extract specimen, without the use of a rib spreader. In PURE, 
minimum access window enables an operator to use scissors just like 
the open thoracotomy. Technique in both groups was in the same 
manner. Short-time clinical outcomes and long-term prognosis was 
compared prospectively. 
Results: Women tended to prefer PURE to ASSIST (20/36 vs. 13/5, 
p<0.05). Operation time in PURE was signiﬁcantly longer those in 
ASSIST (226 vs. 172 min., p<0.0001). Total discharge from the chest 
drainage tube was signiﬁcantly less in PURE than in ASSIST (696 
vs. 1066 ml, p<0.05) Mean length of hospital stay was signiﬁcantly 
shortened in PURE in comparison with those in ASSIST (7.8 vs.13.2 
days, p<0.0001). Dose of suppository painkiller (declofenac sodium) 
was less in PURE within one week after the surgery (12.5 vs. 65.6 mg, 
p<0.001). More cases in ASSIST also received intramuscular painkiller 
injection (pentazocine). Postoperative morbidity was signiﬁcantly 
reduced in PURE (7/56 vs. 7/18, p<0.05). Numbers dissected medias-
tinal lymph nodes were equivalent between the two groups. The 3-year 
disease-free and overall survival rates were also very close among the 
two groups. 
Conclusions: Minimally invasive VATS lobectomy under a pure thora-
coscope-view gave patients early recovery from surgery in association 
with the chest wall destruction, especially regarding the reduction of 
postthoracotomy pain in patients-oriented prospective study. It also 
achieved quality of mediastinal lymph node dissection and good prog-
nosis as an acceptable cancer operation for peripheral T1N0 NSCLC. 
A4-07 Surgery, Mon, 13:45 - 15:30
Prognostic factors for survival of stage I non-small cell lung cancer 
(NSCLC) patients: a population-based analysis of 19,702 stage I 
patients in the California Cancer Registry (CCR) from 1989 to 
2003 
Ou, Sai-Hong I.1 Zell, Jason A.1 Ziogas, Argyrios2 Anton-Culver, Hoda3 
1 Chao Family Comprehensive Cancer Center, Orange, CA, USA 2 
Genetic Epidemiology Cancer Institute, Irvine, CA, USA 3 Genetic 
Epidemiology Research Institute, Irvine, CA, USA 
Purpose: Platinum-based adjuvant chemotherapy in randomized trials 
has failed to provide a survival beneﬁt in resected stage I non-small-
cell lung cancer (NSCLC). Using data from California Cancer Registry 
(CCR), we explored factors that have detrimental effects on survival in 
stage I NSCLC to identify a subset of patients at high risk for relapse 
and subsequent mortality. 
Methods: 19,702 incident cases of stage I NSCLC in the CCR between 
1989 and 2003 were identiﬁed and subgrouped into stage IA and IB 
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disease. Patient demographic factors, tumor characteristics and treat-
ment delivered were examined. Kaplan-Meier survival curves were 
calculated to estimate survival rates. Cox proportional hazards ratios 
were used to identify independent prognostic factors for survival. 
Results: Advanced age at diagnosis, male sex, low socioeconomic 
status (SES), non-surgical treatment, and poor histologic grade (stage 
IA NSCLC: hazard ratio [HR] = 1.14; 95% conﬁdence interval [CI]: 
1.08 - 1.19; stage IB NSCLC: HR = 1.11; 95% CI: 1.07 - 1.16) were 
associated with increased mortality risk on multivariate analysis. 
Non-upper lobar tumor location (right middle lobe, right and left lower 
lobes) and tumor size ≥ 4 cm (vs. < 4 cm; HR = 1.22; 95% CI = 1.15-
1.30) were additional factors with increased mortality risk among stage 
IB patients. Bronchioloalveolar carcinoma and Asian ethnicity were 
associated with decreased mortality risk in stage I NSCLC.
Conclusions: Stage I NSCLC with poorly-differentiated histology and 
stage IB NSCLC with non-upper lobar tumor location or tumor size ≥ 4 
cm carried increased mortality risk. 
A=well-diﬀerentiated, B=moderately-diﬀerentiated, C=poorly-diﬀerenti-
ated, D=undiﬀerentiated
A=upper lobar tumor location, B=non-upper lobar tumor location
Session A5: Molecular Targets 
Monday, September 3
A5-01 Molecular Targets, Mon, 13:45 - 15:30
Epidermal growth factor receptor (EGFR) gene amplification 
in non-small cell lung cancer (NSCLC): molecular patterns and 
sensitivity to tyrosine kinase inhibitors
Skokan, Margaret C.; Gajapathy, Sujatha; Xiao, Yun; Franklin, Wilbur 
A.; Hirsch, Fred R.; Bunn, Paul A. Jr.; Varella-Garcia, Marileila 
University of Colorado, Aurora, CO, USA
Background: Gene ampliﬁcation is a cellular process characterized 
by selective increase in the copy numbers of a DNA segment including 
one or more genes. The phenomenon ampliﬁes the phenotype conferred 
by these genes and is known to be a major source for overexpression 
of oncogenes in cancer. In addition, ampliﬁed and overexpressed genes 
have been targeted in developmental therapeutic approaches, improving 
survival and reducing side effects of treatment. In NSCLC, EGFR is an 
example of these two situations: gene ampliﬁcation associates with pro-
tein overexpression and anti-EGFR approaches have been developed 
as antibodies and small molecules (TKI) that inhibit the tyrosine kinase 
domain of the gene. This study investigated the patterns of EGFR gene 
ampliﬁcation detected in NSCLC and their association with sensitivity 
to TKIs.
Methods: Dual-color FISH assays with LSI SO EGFR/SG CEP 7 (Vy-
sis/Abbott Molecular) were performed in tumors from 1225 NSCLC 
patients treated with geﬁtinib or erlotinib. EGFR gene ampliﬁcation 
was detected in 102 specimens (8.3%) and molecular patterns were rec-
ognized. Outcome to treatment included response according to RECIST 
criteria, time to progression and overall survival.
Results: Ampliﬁed genomic segments were manifested as two rec-
ognizable forms: homogeneously staining regions (HSR), which are 
repeated genomic regions located intra-chromosomally, were found in 
100 (98%) tumors; and double minute chromosomes (DM), which are 
extra-chromosomal segments of ampliﬁed DNA, were found. in two 
cases. Among the HSC cases, 47 tumors had a large number of EGFR 
copies per cluster (10 to >50) while 25 had a smaller number (4 to >10 
copies per cluster). In all these cases the signals were loosely arranged. 
In 12 tumors, the clusters comprised very tightly arranged signals, mak-
ing the enumeration practically impossible. In 9 tumors, the EGFR sig-
nals had an abnormally large and bright presentation although multiple 
spots were not visible. Another clustered pattern consisted of co-local-
ization of EGFR and CEP 7 signals, in which the number of repeats 
were high (4 tumors) or low (3 tumors). In these cases, sequences of 
CEP 7 were either included in the amplicon or interspaced with EGFR 
sequences. The distribution of EGFR-ampliﬁed cells in the tumor 
section was restricted to some foci in 18% of cases, and was diffusely 
spread throughout the entire specimen in 82% of cases. 
Conclusions: Patterns of EGFR gene ampliﬁcation in NSCLC are 
complex and heterogeneous. Accurate laboratorial diagnosis is critical 
for applicability of this phenomenon as a marker to select patients for 
therapy with EGFR TKIs. Correlation of the distinct patterns of EGFR 
gene ampliﬁcation with sensitivity to TKIs is ongoing and will be 
presented at the meeting.
